Utilizing Response- and Biology-Based Risk Factors to Guide Therapy in Patients With Non-high-Risk Neuroblastoma: A Groupwide Historically Controlled Phase III Study
S
Sandeep Batra, MD
Primary Investigator
Administratively Closed
1 years or below
All
Phase
N/A
2 Locations
Brief description of study
This phase III trial studies how well response and biology-based risk factor-guided therapy works in treating younger patients with non-high risk neuroblastoma.
Detailed description of study
This phase III trial studies how well response and biology-based risk factor-guided therapy works in treating younger patients with non-high risk neuroblastoma.
Eligibility of study
You may be eligible for this study if you meet the following criteria:
- Conditions: neuroblastoma
-
Age: 1 years or below
-
Gender: All
Inclusion Criteria
12 months of age at diagnosis with INRG stage L1 or stage M neuroblastoma or nrollment on ANBLOOB1 is required for all newly diagnosed patients
Must have newly diagnosed v-myc avian myelocytomatosis viral oncogene neuroblastoma derived homolog (MYCN) non-amplified neuroblastoma or MYCN non-amplified ganglioneuroblastoma verified by histology
Exclusion Criteria
Patients with MYCN amplified tumors
Additional Information:12 months of age at diagnosis with INRG stage L1 or stage M neuroblastoma or nrollment on ANBLOOB1 is required for all newly diagnosed patients
Must have newly diagnosed v-myc avian myelocytomatosis viral oncogene neuroblastoma derived homolog (MYCN) non-amplified neuroblastoma or MYCN non-amplified ganglioneuroblastoma verified by histology
Exclusion Criteria
Patients with MYCN amplified tumors
Participants will not be paid for their participation.
Updated on
11 Nov 2025.
Study ID: PHO-COG-FALLON-ANBL1232, 1410350695
